Silence Therapeutics plc
SLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $159 | $224 | $142 | $24,328 |
| % Growth | -29% | 57.7% | -99.4% | – |
| Cost of Goods Sold | $64 | $85 | $54 | $1,606 |
| Gross Profit | $95 | $139 | $88 | $22,722 |
| % Margin | 59.7% | 62.1% | 62% | 93.4% |
| R&D Expenses | $20,544 | $17,647 | $20,813 | $20,405 |
| G&A Expenses | $5,795 | $5,131 | $7,684 | $5,395 |
| SG&A Expenses | $5,795 | $5,131 | $7,684 | $5,395 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,324 | $0 | -$0 |
| Operating Expenses | $26,339 | $24,102 | $28,497 | $25,800 |
| Operating Income | -$26,244 | -$23,963 | -$28,409 | -$3,078 |
| % Margin | -16,505.7% | -10,697.8% | -20,006.3% | -12.7% |
| Other Income/Exp. Net | $5,287 | -$3,381 | -$121 | $26,815 |
| Pre-Tax Income | -$20,957 | -$27,344 | -$28,530 | $23,736 |
| Tax Expense | $1 | $10 | $0 | $9,562 |
| Net Income | -$20,958 | -$27,354 | -$28,530 | $14,174 |
| % Margin | -13,181.1% | -12,211.6% | -20,091.5% | 58.3% |
| EPS | -1.32 | -1.74 | -1.8 | 0.9 |
| % Growth | 24.1% | 3.3% | -300% | – |
| EPS Diluted | -1.32 | -1.74 | -1.8 | 0.9 |
| Weighted Avg Shares Out | 15,745 | 15,744 | 15,742 | 15,553 |
| Weighted Avg Shares Out Dil | 15,745 | 15,744 | 15,742 | 15,553 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $887 |
| Interest Expense | $0 | $0 | $0 | -$11,545 |
| Depreciation & Amortization | $156 | $148 | $138 | $119 |
| EBITDA | -$20,801 | -$22,491 | -$28,271 | $7,193 |
| % Margin | -13,082.4% | -10,040.6% | -19,909.2% | 29.6% |